Recent Quotes (30 days)

You have no recent quotes
chg | %

QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
0.0000 (0.00%)
Oct 21 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.03 - 0.03
52 week 0.02 - 0.95
Open 0.03
Vol / Avg. 317,649.00/453,454.00
Mkt cap 3.45M
P/E     -
Div/yield     -
EPS -0.08
Shares 164.19M
Beta     -
Inst. own     -
Nov 19, 2014
QRxPharma Ltd Annual General Meeting Add to calendar
Oct 29, 2014
QRxPharma Ltd Annual Shareholders Meeting - 10:00AM GMT+11 - Add to calendar
Aug 27, 2014
Preliminary 2014 QRxPharma Ltd Earnings Release

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -16418.00% -1991.19%
Operating margin -15664.00% -1990.30%
EBITD margin - -1979.85%
Return on average assets -113.82% -113.38%
Return on average equity -128.57% -140.18%
CDP Score - -


Level 1, 194 Miller Street
+61-2-94928021 (Phone)
+61-2-89200314 (Fax)

Website links


QRxPharma Limited is a commercial-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management. The Company�s complementary pain management product formulations- in both early and late stage clinical development, which include: MOXDUO IR, an immediate release oral capsule for acute pain; MOXDUO CR, a controlled release oral tablet chronic pain; and MOXDUO IV, an intravenous formulation for moderate to severe hospital-based pain. The Company is developing Dual Opioid formulation for treating patients with moderate to server acute or chronic pain. The Company�s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

Officers and directors

Edward M. Rudnic Ph.D. Chief Executive Officer
Chris J Campbell Chief Financial Officer, Company Secretary
Age: 48
M. Janette Dixon Vice President - Global Business Development